They help to eliminate bile and toxins from the intestines
Exenatide was the worlds first clinically used GLP-1RA, developed in 1995 and approved for the treatment of type 2 diabetes mellitus (T2DM) in 2005 due to its proven ability to regulate postprandial glucose levels effectively (DeFronzo et al., 2005
No long-term human dose-response desensitization study exists for either peptide, but the mechanism is real and users relying on twice-daily or three-times-daily injection schedules indefinitely are working against basic receptor pharmacology
When to call your doctor: Red flags You should contact your doctor immediately if you experience any of the following: Difficulty breathing or shortness of breath, especially if it comes on suddenly Sudden swelling of the face, lips, tongue, or throat, or unexplained severe swelling anywhere in the body Severe dizziness, fainting, or feeling like you might pass out Vision changes, such as blurred vision, double vision, or sudden loss of vision Severe or persistent headaches that are unusual for you These symptoms are not mild side effects
Currently, pegvisomant is the only clinically used GHR inhibitor
The standard approach is to take your last dose of the old medication on its normal schedule and start the new medication on what would have been your next scheduled injection day
